Top

Published in:

01-11-2020 | Glioblastoma | Review Article

A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know

Authors: P. D. Delgado-López, P. Saiz-López, R. Gargini, E. Sola-Vendrell, S. Tejada

Published in: Clinical and Translational Oncology | Issue 11/2020

Abstract

The molecular biology of human glioma is a complex and fast-growing field in which basic research needs to meet clinical expectations in terms of anti-tumor efficacy. Although much effort is being done in molecular biology research, significant contribution to the quality of life and overall survival still lacks. The vastness of molecular biology literature makes it virtually impossible for clinicians to keep up to date in the field. This paper reviews some practical concepts regarding glioma tumorigenesis from the clinician’s perspective. Five main aspects are discussed: major intracellular signaling pathways involved in glioma formation; genomic, epigenetic and transcriptomic relevant features of glioma; the prognostic and predictive values of molecular markers according to the new WHO classification of glial tumors; the importance of molecular and cellular heterogeneity in glioblastoma, responsible for its therapy resistance; and the interaction between glioma and the immune system, in view of the novel and promising targeted therapies.

Delgado-López PD, Corrales-García EM, Martino J, Lastra-Aras E, Dueñas-Polo MT. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. Clin Transl Oncol. 2017;19(8):931–44. https://doi.org/10.1007/s12094-017-1631-4.CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. https://doi.org/10.1016/S1470-2045(09)70025-7.CrossRefPubMed

Duffau H. Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective. Curr Opin Oncol. 2018;30(6):383–9. https://doi.org/10.1097/CCO.0000000000000483.CrossRefPubMed

Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–71.CrossRefPubMed

Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol. 2017;135(1):129–39. https://doi.org/10.1007/s11060-017-2559-9.CrossRefPubMed

Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives. Biomed Res Int. 2017;2017:8013575. https://doi.org/10.1155/2017/8013575.CrossRefPubMedPubMedCentral

Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014;37(6):E11. https://doi.org/10.3171/2014.9.FOCUS14521.CrossRefPubMed

Ramos AD, Magge RS, Ramakrishna R. Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg. 2018;116:495–504. https://doi.org/10.1016/j.wneu.2018.04.021.CrossRefPubMed

Zong H, Verhaak RG, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn. 2012;12(4):383–94. https://doi.org/10.1586/erm.12.30.CrossRefPubMedPubMedCentral

10.

Braganza MZ, Kitahara CM, de González AB, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316–24. https://doi.org/10.1093/neuonc/nos208.CrossRefPubMedPubMedCentral

11.

Rous P. A transmissible avian neoplasm (Sarcoma of the common fowl) by Peyton Rous, M.D., experimental Medicine for Sept. 1, 1910, vol. 12, pp. 696–705. J Exp Med. 1979;150(4):738–53.CrossRefPubMed

12.

Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396–8.CrossRefPubMed

13.

Javaid N, Choi S. Acetylation- and methylation-related epigenetic proteins in the context of their targets. Genes (Basel). 2017. https://doi.org/10.3390/genes8080196.CrossRef

14.

Geraldo LHM, Garcia C, da Fonseca ACC, Dubois LGF, de Sampaio E, Spohr TCL, Matias D, et al. Glioblastoma therapy in the age of molecular medicine. Trends Cancer. 2019;5(1):46–65. https://doi.org/10.1016/j.trecan.2018.11.002.CrossRefPubMed

15.

Lu QR, Qian L, Zhou X. Developmental origins and oncogenic pathways in malignant brain tumors. Wiley Interdiscip Rev Dev Biol. 2019;8(4):e342. https://doi.org/10.1002/wdev.342.CrossRefPubMedPubMedCentral

16.

Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012;338(6110):1080–4. https://doi.org/10.1126/science.1226929.CrossRefPubMedPubMedCentral

17.

Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152(1–2):25–38. https://doi.org/10.1016/j.cell.2012.12.012.CrossRefPubMed

18.

Gulaia V, Kumeiko V, Shved N, Cicinskas E, Rybtsov S, Ruzov A, et al. Molecular mechanisms governing the stem cell's fate in brain cancer: factors of stemness and quiescence. Front Cell Neurosci. 2018;12:388. https://doi.org/10.3389/fncel.2018.00388.CrossRefPubMedPubMedCentral

19.

Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–31.CrossRefPubMed

20.

Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010;16(4):1094–9. https://doi.org/10.1158/1078-0432.CCR-09-0787.CrossRefPubMedPubMedCentral

21.

Meletis K, Wirta V, Hede SM, Nistér M, Lundeberg J, Frisén J. p53 suppresses the self-renewal of adult neural stem cells. Development. 2006;133(2):363–9.CrossRefPubMed

22.

Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99.CrossRefPubMed

23.

Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol. 1993;52(1):31–8.CrossRefPubMed

24.

van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst. 1994;86(13):1011–7.CrossRefPubMed

25.

Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 2005;8(2):119–30.CrossRefPubMedPubMedCentral

26.

Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res. 2004;64(21):7773–9.CrossRefPubMed

27.

Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA, et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0–G1 cell cycle entry. Proc Natl Acad Sci USA. 2006;103(1):111–6.CrossRefPubMed

28.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455(7216):1129–33. https://doi.org/10.1038/nature07443.CrossRefPubMedPubMedCentral

29.

Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008;68(9):3286–94. https://doi.org/10.1158/0008-5472.CAN-07-6867.CrossRefPubMedPubMedCentral

30.

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e11. https://doi.org/10.1016/j.cell.2018.02.052.CrossRefPubMedPubMedCentral

31.

Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Sci Rep. 2013;2(3):2652. https://doi.org/10.1038/srep02652.CrossRef

32.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013. https://doi.org/10.1126/scisignal.2004088.CrossRefPubMedPubMedCentral

33.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095.CrossRefPubMed

34.

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. https://doi.org/10.1038/nature07385.CrossRef

35.

Teo WY, Sekar K, Seshachalam P, Shen J, Chow WY, Lau CC, et al. Relevance of a TCGA-derived glioblastoma subtype gene-classifier among patient populations. Sci Rep. 2019;9(1):7442. https://doi.org/10.1038/s41598-019-43173-y.CrossRefPubMedPubMedCentral

36.

Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–63. https://doi.org/10.1016/j.cell.2015.12.028.CrossRefPubMedPubMedCentral

37.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. https://doi.org/10.1016/j.cell.2013.09.034.CrossRefPubMedPubMedCentral

38.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentral

39.

Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170(5):1445–533.CrossRefPubMedPubMedCentral

40.

Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–72. https://doi.org/10.1158/1078-0432.CCR-12-3002.CrossRefPubMed

41.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMed

42.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–98. https://doi.org/10.1056/NEJMoa1402121.CrossRef

43.

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–22. https://doi.org/10.1016/j.ccr.2010.03.017.CrossRefPubMedPubMedCentral

44.

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110–4. https://doi.org/10.1038/nature16490.CrossRefPubMed

45.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumors. Nature. 2018;555(7697):469–74. https://doi.org/10.1038/nature26000.CrossRefPubMedPubMedCentral

46.

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.CrossRefPubMed

47.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. https://doi.org/10.1016/j.ccr.2009.12.020.CrossRefPubMedPubMedCentral

48.

Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24(3):331–46. https://doi.org/10.1016/j.ccr.2013.08.001.CrossRefPubMed

49.

Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014;20(22):5612–9. https://doi.org/10.1158/1078-0432.CCR-14-0834.CrossRefPubMedPubMedCentral

50.

Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8(6):425–37. https://doi.org/10.1038/nrc2397.CrossRefPubMedPubMedCentral

51.

Ahn GO, Brown JM. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis. 2009;12(2):159–64. https://doi.org/10.1007/s10456-009-9135-7.CrossRefPubMedPubMedCentral

52.

Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006;66(18):9054–64.CrossRefPubMed

53.

Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005;53(8):997–1002.CrossRefPubMed

54.

Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA. 2011;108(11):4274–80. https://doi.org/10.1073/pnas.1016030108.CrossRefPubMedPubMedCentral

55.

Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013;153(1):139–52. https://doi.org/10.1016/j.cell.2013.02.021.CrossRefPubMedPubMedCentral

56.

Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol. 2012;181(4):1126–41. https://doi.org/10.1016/j.ajpath.2012.06.030.CrossRefPubMedPubMedCentral

57.

Park JS, Kim IK, Han S, Park I, Kim C, Bae J, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2016;30(6):953–67. https://doi.org/10.1016/j.ccell.2016.10.018.CrossRefPubMed

58.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon: IARC Press; 2016.

59.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. 4th ed. Lyon: IARC Press; 2007.

60.

Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, et al. Molecular testing of brain tumor. J Pathol Transl Med. 2017;51(3):205–23. https://doi.org/10.4132/jptm.2017.03.08.CrossRefPubMedPubMedCentral

61.

Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M. cIMPACT-NOW UPDATE 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 2018;135(3):481–4.CrossRefPubMed

62.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.CrossRefPubMedPubMedCentral

63.

Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–77. https://doi.org/10.5114/wo.2014.47136.CrossRef

64.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–18.CrossRefPubMed

65.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology. 2012;14:100–8.

66.

Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3–K27M mutation: A series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.CrossRefPubMed

67.

Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–37.CrossRefPubMed

68.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405. https://doi.org/10.1007/s00401-011-0802-6.CrossRefPubMed

69.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.78.9990.CrossRefPubMedPubMedCentral

70.

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014;16(7):896–913.CrossRefPubMedPubMedCentral

71.

Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013;123(9):3659–63. https://doi.org/10.1172/JCI67229.CrossRefPubMedPubMedCentral

72.

Kalpathy-Cramer J, Gerstner ER, Emblem KE, Andronesi O, Rosen B. Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res. 2014;74(17):4622–37. https://doi.org/10.1158/0008-5472.CAN-14-0383.CrossRefPubMedPubMedCentral

73.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33(7):1349–55. https://doi.org/10.3174/ajnr.A2950.CrossRefPubMedPubMedCentral

74.

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93. https://doi.org/10.1126/science.1239947.CrossRefPubMed

75.

Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014;16(1):81–91. https://doi.org/10.1093/neuonc/not159.CrossRefPubMed

76.

Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, et al. InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma. Clin Cancer Res. 2016;22(7):1767–76. https://doi.org/10.1158/1078-0432.CCR-15-1677.CrossRefPubMed

77.

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–401. https://doi.org/10.1126/science.1254257.CrossRefPubMedPubMedCentral

78.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.CrossRefPubMed

79.

Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522–6. https://doi.org/10.1038/nature11287.CrossRefPubMedPubMedCentral

80.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.CrossRefPubMed

81.

Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014;157(3):580–94. https://doi.org/10.1016/j.cell.2014.02.030.CrossRefPubMedPubMedCentral

82.

Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011;8(5):482–5. https://doi.org/10.1016/j.stem.2011.04.013.CrossRefPubMedPubMedCentral

83.

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337–41.CrossRefPubMedPubMedCentral

84.

Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuro Pharmacol. 2013;8:840–56.

85.

Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell dysfunction in glioblastoma: applying a new framework. Clin Cancer Res. 2018;24(16):3792–802. https://doi.org/10.1158/1078-0432.CCR-18-0047.CrossRefPubMedPubMedCentral

86.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8.CrossRefPubMed

87.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8. https://doi.org/10.3171/2011.2.JNS10998.CrossRefPubMed

88.

Díez Valle R, Becerra Castro V, Marigil Sánchez M, Gállego Pérez-Larraya J, Núñez-Córdoba JM, Tejada SS. Results of a policy of fast tapering of steroids after resection surgery in glioblastoma. World Neurosurg. 2018;109:e845–e852852. https://doi.org/10.1016/j.wneu.2017.10.110.CrossRefPubMed

89.

Platten M. EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough? Neuro Oncol. 2017;19(11):1425–6. https://doi.org/10.1093/neuonc/nox167.CrossRefPubMedPubMedCentral

90.

Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate M, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15(1):104. https://doi.org/10.1186/s12967-017-1202-z.CrossRefPubMedPubMedCentral

91.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25(3):470–6. https://doi.org/10.1038/s41591-018-0339-5.CrossRefPubMed

92.

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–27. https://doi.org/10.1200/JCO.2017.75.8219.CrossRefPubMedPubMedCentral

93.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–61. https://doi.org/10.1056/NEJMoa1716435.CrossRefPubMedPubMedCentral

94.

Philbrick BD, Adamson DC. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin Investig Drugs. 2019;28(3):207–16. https://doi.org/10.1080/13543784.2019.1572112.CrossRefPubMed

95.

Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014;16(Suppl 8):7–13. https://doi.org/10.1093/neuonc/nou232.CrossRef

96.

Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma—an update. Crit Rev Oncol Hematol. 2016;99:389–408. https://doi.org/10.1016/j.critrevonc.2016.01.018.CrossRefPubMed

97.

Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457–72. https://doi.org/10.1093/annonc/mdx106.CrossRefPubMedPubMedCentral

98.

Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21(117):373–80.PubMed

99.

Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;21(3):4. https://doi.org/10.1186/s40478-014-0180-0.CrossRef

Title: A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know
Authors: P. D. Delgado-López
P. Saiz-López
R. Gargini
E. Sola-Vendrell
S. Tejada
Publication date: 01-11-2020
Publisher: Springer International Publishing
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Glioblastoma
Glioma
Epigenetics
Published in: Clinical and Translational Oncology / Issue 11/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02340-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2020

The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials

Radiotherapy after prostatectomy in high‑risk prostate cancer

Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck

Safety in radiation oncology: transposition of directive 2013/59/EURATOM in the Spanish Radiation Oncology Departments—recommendations for its adequate and effective application

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer